Investment Thesis
DNA X faces imminent financial distress with negative stockholders equity (-$8M), critical liquidity crisis ($1.3M cash vs -$23.5M operating cash burn), and ongoing operational losses despite 14.5% revenue growth. The company will exhaust cash reserves within weeks at current burn rates and cannot service debt obligations.
Strengths
- Revenue growth of 14.5% YoY demonstrates market demand
- Gross margin of 25% indicates product has some pricing power
- EPS improved 77.7% YoY (though remains deeply negative)
Risks
- Negative stockholders equity of -$8M (technical insolvency)
- Critical liquidity: $1.3M cash with -$23.5M operating cash burn (weeks of runway)
- Negative operating margins (-12.3%) with losses expanding despite revenue growth
- Current ratio 0.60x / Quick ratio 0.37x unable to cover near-term obligations
- Negative interest coverage (-5.7x) - cannot service $5.1M debt from operations
- Operating cash flow deterioration dominates revenue gains
Key Metrics to Watch
- Operating cash flow (currently -$23.5M)
- Cash burn rate and months of runway remaining
- Stockholders equity recovery timeline
- Debt refinancing capability and maturity schedule
Financial Metrics
Revenue
44.1M
Net Income
-20.7M
EPS (Diluted)
$-28.58
Free Cash Flow
-23.7M
Total Assets
43.9M
Cash
1.3M
Profitability Ratios
Gross Margin
25.0%
Operating Margin
-12.3%
Net Margin
-46.8%
ROE
N/A
ROA
-47.1%
FCF Margin
-53.8%
Balance Sheet & Liquidity
Current Ratio
0.60x
Quick Ratio
0.37x
Debt/Equity
N/A
Debt/Assets
115.3%
Interest Coverage
-5.72x
Long-term Debt
5.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-16T08:45:19.192786 |
Data as of: 2025-12-31 |
Powered by Claude AI